The optimal revascularization strategy in patients with diabetes has been settled by the Freedom trial. This trial randomized 1900 patients with diabetes and multivessel CAD already receiving aggressive medical therapy, to CABG or DES. The 5-year primary composite outcome occurred in 26.6% of the PCI group and 18.7% of the CABG group (P=0.005). Crucially, the benefit of CABG was driven by highly significant absolute reductions in both death (5.4%; P=0.049) and myocardial infarction (7.9%; P<0.001).
